Terms: = Leukemia AND MPL, TPOR, P40238, 4352, ENSG00000117400, CD110, MPLV, C-MPL, RP1-92O14_1 AND Clinical Outcome
941 results:
1. [The value of minimal residual disease and IKZF1 deletion for predicting prognosis in adult patients with B-cell acute lymphoblastic leukemia].
Deng SY; Ou JW; Huang ZC; Chen JJ; Cai ZH; Liu QF; Zhou HS
Zhonghua Xue Ye Xue Za Zhi; 2024 Mar; 45(3):257-263. PubMed ID: 38716597
[No Abstract] [Full Text] [Related]
2. Combining CRISPR-Cas9 and TCR exchange to generate a safe and efficient cord blood-derived T cell product for pediatric relapsed AML.
Lo Presti V; Meringa A; Dunnebach E; van Velzen A; Moreira AV; Stam RW; Kotecha RS; Krippner-Heidenreich A; Heidenreich OT; Plantinga M; Cornel A; Sebestyen Z; Kuball J; van Til NP; Nierkens S
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38580329
[TBL] [Abstract] [Full Text] [Related]
3. clinical Analysis of Pediatric Acute Megakaryocytic leukemia With CBFA2T3-GLIS2 Fusion Gene.
Du Y; Yang L; Qi S; Chen Z; Sun M; Wu M; Wu B; Tao F; Xiong H
J Pediatr Hematol Oncol; 2024 Mar; 46(2):96-103. PubMed ID: 38315896
[TBL] [Abstract] [Full Text] [Related]
4. A Comprehensive Metabolism-Related Gene Signature Predicts the Survival of Patients with Acute Myeloid leukemia.
Zhai Y; Shen H; Wei H
Genes (Basel); 2023 Dec; 15(1):. PubMed ID: 38254953
[TBL] [Abstract] [Full Text] [Related]
5. Patient-Specific Measurable Residual Disease Markers Predict outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell Transplantation.
Tobiasson M; Pandzic T; Illman J; Nilsson L; Weström S; Ejerblad E; Olesen G; Björklund A; Olsnes Kittang A; Werlenius O; Lorentz F; Rasmussen B; Cammenga J; Weber D; Lindholm C; Wiggh J; Dimitriou M; Moen AE; Yip Lundström L; von Bahr L; Baltzer-Sollander K; Jädersten M; Kytölä S; Walldin G; Ljungman P; Groenbaek K; Mielke S; Jacobsen SEW; Ebeling F; Cavelier L; Smidstrup Friis L; Dybedal I; Hellström-Lindberg E
J Clin Oncol; 2024 Apr; 42(12):1378-1390. PubMed ID: 38232336
[TBL] [Abstract] [Full Text] [Related]
6. Validation of genes for H-ARS severity prediction in leukemia patients - interspecies comparison, challenges, and promises.
Schwanke D; Valente M; Ostheim P; Schüle S; Bobyk L; Drouet M; Riccobono D; Magné N; Daguenet E; Stewart SJ; Muhtadi R; Port M; Abend M
Int J Radiat Biol; 2024; 100(4):527-540. PubMed ID: 38227483
[TBL] [Abstract] [Full Text] [Related]
7. Prediction of outcomes for high-count monoclonal B lymphocytosis using an epigenetic and immunogenetic signature.
Abdelbaky SB; Giacopelli B; Rabe KG; Yamaguchi K; Wu YZ; Yan H; Shanafelt TD; Parikh SA; Ding W; Hampel PJ; Brown S; Cerhan JR; Vachon CM; Kay NE; Hanson CA; Parker AS; Braggio E; Slager SL; Oakes CC
Blood; 2024 Apr; 143(17):1752-1757. PubMed ID: 38194687
[TBL] [Abstract] [Full Text] [Related]
8. The fifth edition of the WHO classification of mature B-cell neoplasms: open questions for research.
Coupland SE; Du MQ; Ferry JA; de Jong D; Khoury JD; Leoncini L; Naresh KN; Ott G; Siebert R; Xerri L;
J Pathol; 2024 Mar; 262(3):255-270. PubMed ID: 38180354
[TBL] [Abstract] [Full Text] [Related]
9. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
10. Immunologic Targets in AML.
Ritz J
Blood Cancer Discov; 2023 Nov; 4(6):430-432. PubMed ID: 37847743
[TBL] [Abstract] [Full Text] [Related]
11. Identification of cellular senescence-related signature for predicting prognosis and therapeutic response of acute myeloid leukemia.
Zhong F; Yang Y; Yao F; Liu J; Yu X; Wang XL; Huang B; Wang XZ
Aging (Albany NY); 2023 Oct; 15(20):11217-11226. PubMed ID: 37845004
[TBL] [Abstract] [Full Text] [Related]
12. Genetic Polymorphism Study of IDH 1/2 and TET2 Genes in Acute Myeloid leukemia Patients.
Atef M; Shafik NF; H A Hassan N; Allam RM; El-Meligui YM; Abdelaziz H
Asian Pac J Cancer Prev; 2023 Sep; 24(9):3169-3182. PubMed ID: 37774069
[TBL] [Abstract] [Full Text] [Related]
13. BCR::ABL1 kinase domain mutation testing and clinical outcome in a nationwide chronic myeloid leukemia patient population.
Kockerols C; Valk PJM; Blijlevens NMA; Cornelissen JJ; Dinmohamed AG; Geelen I; Hoogendoorn M; Janssen JJWM; Daenen LGM; Reijden BAV; Westerweel PE
Eur J Haematol; 2023 Dec; 111(6):938-945. PubMed ID: 37731314
[TBL] [Abstract] [Full Text] [Related]
14. Adult T-cell leukemia/lymphoma in HTLV-1 non-endemic regions.
de Mendoza C; Rando A; Miró E; Pena MJ; Rodríguez-Avial I; Ortega D; González-Praetorius A; Reina G; Pintos I; Pozuelo MJ; Soriano V;
J Clin Virol; 2023 Oct; 167():105578. PubMed ID: 37660433
[TBL] [Abstract] [Full Text] [Related]
15. Characteristics and outcome of infectious complications after autologous hematopoietic cell transplantation in multiple myeloma patients.
Jandial A; Lad D; Jain A; Khadwal A; Singh C; Prakash G; Suri V; Sreedharanunni S; Sachdeva MUS; Ray P; Varma N; Varma S; Malhotra P
Transpl Infect Dis; 2023 Oct; 25(5):e14123. PubMed ID: 37573150
[TBL] [Abstract] [Full Text] [Related]
16. [Efficacy and safety of secondary allogeneic hematopoietic stem cell transplantation in 70 patients with recurrent hematologic malignancies after transplantation].
Han TT; Liu Y; Chen Y; Zhang YY; Fu HX; Yan CH; Mo XD; Wang FR; Wang JZ; Han W; Chen YY; Chen H; Sun YQ; Cheng YF; Wang Y; Zhang XH; Huang XJ; Xu LP
Zhonghua Xue Ye Xue Za Zhi; 2023 Jun; 44(6):458-464. PubMed ID: 37550200
[No Abstract] [Full Text] [Related]
17. clinical outcome of Mantle Cell Lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression).
Scheubeck G; Jiang L; Hermine O; Kluin-Nelemans HC; Schmidt C; Unterhalt M; Rosenwald A; Klapper W; Evangelista A; Ladetto M; Jerkeman M; Ferrero S; Dreyling M; Hoster E
Leukemia; 2023 Sep; 37(9):1887-1894. PubMed ID: 37495776
[TBL] [Abstract] [Full Text] [Related]
18. Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial.
Schubert ML; Schmitt A; Hückelhoven-Krauss A; Neuber B; Kunz A; Waldhoff P; Vonficht D; Yousefian S; Jopp-Saile L; Wang L; Korell F; Keib A; Michels B; Haas D; Sauer T; Derigs P; Kulozik A; Kunz J; Pavel P; Laier S; Wuchter P; Schmier J; Bug G; Lang F; Gökbuget N; Casper J; Görner M; Finke J; Neubauer A; Ringhoffer M; Wolleschak D; Brüggemann M; Haas S; Ho AD; Müller-Tidow C; Dreger P; Schmitt M
J Hematol Oncol; 2023 Jul; 16(1):79. PubMed ID: 37481608
[TBL] [Abstract] [Full Text] [Related]
19. Pretransplant spleen volume and outcome after hematopoietic stem cell transplantation (HSCT) in patients with acute myeloid leukemia (AML).
Pohlmann A; Bentgens E; Schülke C; Kuron D; Reicherts C; Marx J; Angenendt L; Mikesch JH; Lenz G; Stelljes M; Schliemann C
Ann Hematol; 2023 Sep; 102(9):2543-2553. PubMed ID: 37428201
[TBL] [Abstract] [Full Text] [Related]
20. Leukapheresis and Tisagenlecleucel Manufacturing outcomes in Patients Age <3 Years with Relapsed/Refractory Acute Lymphoblastic leukemia.
Fong D; Tiwari R; Acker C; Clough L; Willert J
Transplant Cell Ther; 2023 Sep; 29(9):579.e1-579.e10. PubMed ID: 37311511
[TBL] [Abstract] [Full Text] [Related]
[Next]